EA200100165A1 - Применение усилителя захвата глюкозы для уменьшения апоптоза - Google Patents
Применение усилителя захвата глюкозы для уменьшения апоптозаInfo
- Publication number
- EA200100165A1 EA200100165A1 EA200100165A EA200100165A EA200100165A1 EA 200100165 A1 EA200100165 A1 EA 200100165A1 EA 200100165 A EA200100165 A EA 200100165A EA 200100165 A EA200100165 A EA 200100165A EA 200100165 A1 EA200100165 A1 EA 200100165A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- application
- cells
- reduce apoptosis
- human
- capture amplifier
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title 1
- 239000008103 glucose Substances 0.000 title 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 210000004413 cardiac myocyte Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 230000004190 glucose uptake Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9815871.0A GB9815871D0 (en) | 1998-07-21 | 1998-07-21 | Novel compound |
| GBGB9815872.8A GB9815872D0 (en) | 1998-07-21 | 1998-07-21 | Novel method |
| GBGB9905387.8A GB9905387D0 (en) | 1999-03-09 | 1999-03-09 | Novel method |
| PCT/GB1999/002361 WO2000004890A1 (en) | 1998-07-21 | 1999-07-21 | Use of glucose uptake enhancer for reducing apoptosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA200100165A1 true EA200100165A1 (ru) | 2001-08-27 |
Family
ID=27269407
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200100165A EA200100165A1 (ru) | 1998-07-21 | 1999-07-21 | Применение усилителя захвата глюкозы для уменьшения апоптоза |
Country Status (25)
| Country | Link |
|---|---|
| EP (2) | EP1098639B1 (enExample) |
| JP (1) | JP2002521326A (enExample) |
| KR (1) | KR20010079551A (enExample) |
| CN (1) | CN1310620A (enExample) |
| AP (1) | AP2001002036A0 (enExample) |
| AT (1) | ATE288746T1 (enExample) |
| AU (1) | AU5053799A (enExample) |
| BG (1) | BG105250A (enExample) |
| BR (1) | BR9912117A (enExample) |
| CA (1) | CA2338211A1 (enExample) |
| DE (1) | DE69923687T2 (enExample) |
| DK (1) | DK1098639T3 (enExample) |
| EA (1) | EA200100165A1 (enExample) |
| ES (1) | ES2237929T3 (enExample) |
| HU (1) | HUP0103199A3 (enExample) |
| ID (1) | ID26986A (enExample) |
| IL (1) | IL140664A0 (enExample) |
| NO (1) | NO20010292L (enExample) |
| OA (1) | OA11579A (enExample) |
| PL (1) | PL345627A1 (enExample) |
| PT (1) | PT1098639E (enExample) |
| SI (1) | SI1098639T1 (enExample) |
| SK (1) | SK1012001A3 (enExample) |
| TR (1) | TR200100207T2 (enExample) |
| WO (1) | WO2000004890A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000043006A1 (en) * | 1999-01-19 | 2000-07-27 | Sankyo Company, Limited | Inhibitor for nerve cell death due to glutamic acid cytotoxicity |
| US6417212B1 (en) | 1999-08-27 | 2002-07-09 | Eli Lilly & Company | Modulators of peroxisome proliferator activated receptors |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10199003I1 (de) * | 1987-09-04 | 2003-06-12 | Beecham Group Plc | Substituierte Thiazolidinionderivate |
| JPH05202042A (ja) * | 1992-01-24 | 1993-08-10 | Sankyo Co Ltd | 糖尿病性合併症治療剤 |
| GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
| IL120443A (en) * | 1996-03-18 | 2000-07-16 | Sankyo Co | Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis |
| GB9611947D0 (en) * | 1996-06-07 | 1996-08-07 | Glaxo Group Ltd | Medicaments |
| US6277819B1 (en) * | 1996-08-30 | 2001-08-21 | Eli Lilly And Company | Use of GLP-1 or analogs in treatment of myocardial infarction |
| EP0958818A1 (en) * | 1996-09-12 | 1999-11-24 | Sankyo Company Limited | Glutathione reductase activity potentiator containing troglitazone |
| GB9721692D0 (en) * | 1997-10-13 | 1997-12-10 | Smithkline Beecham Plc | Novel treatment |
| DE69834508T2 (de) * | 1997-11-19 | 2006-11-23 | Takeda Pharmaceutical Co. Ltd. | Apoptoseinhibitoren |
| AU2781899A (en) * | 1998-02-24 | 1999-09-15 | Trustees Of The University Of Pennsylvania, The | Use of a cardiac purinoceptor to effect cellular glucose uptake |
| AU4005299A (en) * | 1998-05-19 | 1999-12-06 | Regents Of The University Of California, The | Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis |
| US5968960A (en) * | 1999-01-14 | 1999-10-19 | The Regents Of The University Of California | Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism |
-
1999
- 1999-07-21 BR BR9912117-4A patent/BR9912117A/pt not_active IP Right Cessation
- 1999-07-21 CA CA002338211A patent/CA2338211A1/en not_active Abandoned
- 1999-07-21 EP EP99934914A patent/EP1098639B1/en not_active Expired - Lifetime
- 1999-07-21 HU HU0103199A patent/HUP0103199A3/hu unknown
- 1999-07-21 ES ES99934914T patent/ES2237929T3/es not_active Expired - Lifetime
- 1999-07-21 EA EA200100165A patent/EA200100165A1/ru unknown
- 1999-07-21 WO PCT/GB1999/002361 patent/WO2000004890A1/en not_active Ceased
- 1999-07-21 KR KR1020017000925A patent/KR20010079551A/ko not_active Withdrawn
- 1999-07-21 IL IL14066499A patent/IL140664A0/xx unknown
- 1999-07-21 DK DK99934914T patent/DK1098639T3/da active
- 1999-07-21 AU AU50537/99A patent/AU5053799A/en not_active Abandoned
- 1999-07-21 EP EP04078537A patent/EP1516617A2/en not_active Withdrawn
- 1999-07-21 DE DE69923687T patent/DE69923687T2/de not_active Expired - Fee Related
- 1999-07-21 TR TR2001/00207T patent/TR200100207T2/xx unknown
- 1999-07-21 ID IDW20010150A patent/ID26986A/id unknown
- 1999-07-21 OA OA1200100010A patent/OA11579A/en unknown
- 1999-07-21 SK SK101-2001A patent/SK1012001A3/sk unknown
- 1999-07-21 PL PL99345627A patent/PL345627A1/xx not_active Application Discontinuation
- 1999-07-21 PT PT99934914T patent/PT1098639E/pt unknown
- 1999-07-21 AT AT99934914T patent/ATE288746T1/de not_active IP Right Cessation
- 1999-07-21 AP APAP/P/2001/002036A patent/AP2001002036A0/en unknown
- 1999-07-21 JP JP2000560883A patent/JP2002521326A/ja active Pending
- 1999-07-21 CN CN99808983A patent/CN1310620A/zh active Pending
- 1999-07-21 SI SI9930772T patent/SI1098639T1/xx unknown
-
2001
- 2001-01-18 NO NO20010292A patent/NO20010292L/no unknown
- 2001-02-14 BG BG105250A patent/BG105250A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0103199A2 (hu) | 2002-05-29 |
| DE69923687D1 (de) | 2005-03-17 |
| NO20010292D0 (no) | 2001-01-18 |
| AU5053799A (en) | 2000-02-14 |
| TR200100207T2 (tr) | 2001-05-21 |
| CN1310620A (zh) | 2001-08-29 |
| EP1098639A1 (en) | 2001-05-16 |
| EP1098639B1 (en) | 2005-02-09 |
| HK1037865A1 (en) | 2002-02-22 |
| JP2002521326A (ja) | 2002-07-16 |
| NO20010292L (no) | 2001-03-08 |
| SI1098639T1 (enExample) | 2005-08-31 |
| SK1012001A3 (en) | 2001-08-06 |
| ATE288746T1 (de) | 2005-02-15 |
| CA2338211A1 (en) | 2000-02-03 |
| BG105250A (en) | 2001-11-30 |
| KR20010079551A (ko) | 2001-08-22 |
| PT1098639E (pt) | 2005-06-30 |
| ID26986A (id) | 2001-02-22 |
| WO2000004890A1 (en) | 2000-02-03 |
| IL140664A0 (en) | 2002-02-10 |
| ES2237929T3 (es) | 2005-08-01 |
| OA11579A (en) | 2004-06-01 |
| PL345627A1 (en) | 2002-01-02 |
| AP2001002036A0 (en) | 2001-03-31 |
| DK1098639T3 (da) | 2005-06-13 |
| HUP0103199A3 (en) | 2002-08-28 |
| DE69923687T2 (de) | 2006-04-06 |
| EP1516617A2 (en) | 2005-03-23 |
| BR9912117A (pt) | 2001-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1017692E (pt) | 4-heteroaril-tetrahidroquinolinas e sua aplicacao como inibidores da proteina de transferencia de ester de colesterol (ctep) | |
| DK1066052T3 (da) | Mesenchymstamceller til forebyggelse og behandling af immunreaktioner ved transplantationer | |
| EA199800626A1 (ru) | Применение агониста ppar-гамма для лечения синдрома х | |
| EA199901027A1 (ru) | Сложные моноэфиры пробукола для лечения сердечно-сосудистых и воспалительных заболеваний | |
| ES2106965T3 (es) | Nuevas 4-aza-5alfa-androstan-3-onas 7beta-sustituidas como inhibidores de 5alfa-reductasa. | |
| EA200101089A1 (ru) | Новый способ лечения | |
| ATE71298T1 (de) | Immunoregulation. | |
| EE9800387A (et) | Implantatsiooni tõhustamine pärast in vitro viljastamist | |
| IT8621975A0 (it) | Protesi acustica da inserire nell'orecchio. | |
| DE69630955D1 (de) | Immortalisierung bzw. desimmortalisierung von zellen | |
| ATE358473T1 (de) | Diamino-propanol-verbindungen zur behandlung von ischaemien | |
| PT888271E (pt) | Derivados de benzamidina substituidos com derivados de aminoacidos e hidroxiacidos e sua utilizacao como anticoagulantes | |
| NO950405D0 (no) | Glykogenpolysakkarider | |
| ES2058343T3 (es) | Piridinas disubstituidas. | |
| EA200100165A1 (ru) | Применение усилителя захвата глюкозы для уменьшения апоптоза | |
| MX9305196A (es) | Novedosos 2-sacarinilmetil aril carboxilatos utiles como inhibidores de enzima proteolitica y composiciones y metodos de su uso. | |
| PT1067966E (pt) | Composicao oftalmica compreendendo um bloqueador beta | |
| NO890356D0 (no) | Fremgangsmaate til aa utfoere vei- og markkonstruksjoner. | |
| EP0410295A3 (en) | Single-ended chopper stabilized operational amplifier | |
| DE69823227D1 (de) | Kaliumkanalöffner | |
| NO954081L (no) | Cytotoksisk faktor forbundet med disseminert sklerose, dens påvisning og kvantifisering | |
| BR9915767A (pt) | Artigo absorvente dotado de um canal | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin | |
| EA200100164A1 (ru) | Применение усилителя захвата глюкозы для уменьшения постишемического повреждения сердца | |
| ATE329600T1 (de) | Verwendung von tagatose zur verbesserung wichtiger blutfaktoren |